Erkki Nissinen
Overview
Explore the profile of Erkki Nissinen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nissinen E, Mannisto P
Int Rev Neurobiol
. 2010 Nov;
95:73-118.
PMID: 21095460
Catechol-O-methyltransferase (COMT) is an important enzyme in the metabolism of catechol structured compounds such as catecholamines, catecholestrogens, and L-dopa. When combined with decarboxylase inhibitor L-dopa is the most efficacious treatment...
2.
Nissinen E
Int Rev Neurobiol
. 2010 Nov;
95:1-5.
PMID: 21095456
Catechol-O-methyltransferase (COMT) enzyme and its inhibition have been closely related to the treatment of Parkinson's disease (PD) patients with motor fluctuations needing enhancement of their levodopa (L-dopa) therapy (L-dopa/dopa decarboxylase...
3.
4.
Sareila O, Hamalainen M, Nissinen E, Kankaanranta H, Moilanen E
J Pharmacol Exp Ther
. 2007 Nov;
324(2):858-66.
PMID: 18039960
Orazipone [OR-1384; 3-[4-(methylsulfonyl)benzylidene]pentane-2,4-dione] is a novel sulfhydryl-modulating compound that has anti-inflammatory properties in experimental models of asthma and inflammatory bowel disease. In inflammation, inducible nitricoxide synthase (iNOS) generates NO, which...
5.
Kankaanranta H, Zhang X, Tumelius R, Ruotsalainen M, Haikala H, Nissinen E, et al.
J Pharmacol Exp Ther
. 2007 Jul;
323(1):31-8.
PMID: 17620456
Simendans are novel agents used in the treatment of decompensated heart failure. They sensitize troponin C to calcium and open ATP-sensitive potassium channels and have been shown to reduce cardiac...
6.
Kankaanranta H, Ilmarinen P, Zhang X, Nissinen E, Moilanen E
Mol Pharmacol
. 2006 Mar;
69(6):1861-70.
PMID: 16540599
Orazipone is a novel sulfhydryl-reactive compound that has been previously shown to reduce lung eosinophilia in guinea pigs and rats and to inhibit degranulation in mast cells and cytokine production...
7.
Kaheinen P, Pollesello P, Hertelendi Z, Borbely A, Szilagyi S, Nissinen E, et al.
Basic Clin Pharmacol Toxicol
. 2006 Jan;
98(1):74-8.
PMID: 16433895
In order to clarify the mechanisms of the positive inotropic actions of levosimendan and its optical isomer, dextrosimendan, we compared their concentration-dependent effects in intact papillary muscles, permeabilized cardiomyocytes and...
8.
Vendelin J, Laitinen C, Vainio P, Nissinen E, Maki T, Eklund K
Int Immunopharmacol
. 2004 Dec;
5(1):177-84.
PMID: 15589479
Orazipone (OR-1384) and OR-1958 are novel anti-inflammatory sulfhydryl reactive compounds with potential applications in the treatment of chronic obstructive lung disease and colitis. Mast cells are potent immune system cells...
9.
Haasio K, Huotari M, Nissinen E, Mannisto P
J Appl Toxicol
. 2003 Jul;
23(4):213-9.
PMID: 12884403
Catechol-O-methyltransferase (COMT) enzyme is a widely distributed enzyme that catalyses O-methylation of catecholamines and other compounds having a catechol structure. Because there has been some concern about the consequences of...
10.
Haasio K, Koponen A, Penttila K, Nissinen E
Eur J Pharmacol
. 2002 Oct;
453(1):21-6.
PMID: 12393055
Catechol-O-methyl transferase (COMT) inhibitors, entacapone and tolcapone, are used as an adjunctive treatment to L-dopa in Parkinson's disease. Based on their catechol structure, both inhibitors are potential uncoupling agents, but...